Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella Therapeutics presented new clinical data for its lead asset QTORIN rapamycin at the ISSVA World Congress, highlighting robust results from the Phase 3 SELVA study for microcystic lymphatic malformations. In the pediatric cohort (ages 6–11), 100% of participants were rated as 'Much Improved' or 'Very Much Improved' at Week 24, with a mean improvement of +2.46 on the mLM-IGA scale. Additionally, 87% of patients with moderate or worse leaking/bleeding showed significant improvement, addressing a key debilitating symptom. The Phase 2 TOIVA study for cutaneous venous malformations also showed statistically significant improvements in height and appearance scores.
Key figures
- Drug Name
- QTORIN rapamycin
- Phase Of Trial
- Phase 3
- Selva patient satisfaction
- 100%
- Selva bleeding response rate
- 87%
- Selva pediatric response rate
- 100%
- Selva bleeding mean improvement
- +2.48
- Toiva cvm mcss height reduction
- -1.50 points
- Selva pediatric mean improvement
- +2.46
- Selva blinded mlm mcss improvement
- -3.4 points
- Toiva cvm mcss appearance reduction
- -1.43 points
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.